



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 26 June 2024

In compliance with the reporting requirements provided for in article 226 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereon, “**ROVI**” or the “**Company**”) hereby discloses to the Spanish National Securities Market Commission the following

INSIDE INFORMATION

Further to the relevant information published on 7 March 2024, with registration number 27290, regarding the assessment by ROVI of potential strategic alternatives to put in value its assets and in view of the information published in the press today in relation to a potential corporate transaction of ROVI relating to its third party manufacturing services, we hereby inform you that, in the context of the assessment process entrusted to Lazard, ROVI has received from various entities non-binding offers for the acquisition of said business.

The non-binding proposals received are subject to several conditions usual in these transactions, such as carrying out a financial and legal due diligence and the negotiation of satisfactory agreements in the relevant contracts.

ROVI will continue to assess the convenience of a potential transaction. In any event, if ROVI decides to go ahead with any proposal and if the applicable conditions are met and satisfactory agreements are reached, the transaction will remain subject to approval by ROVI's general shareholders' meeting and,



where appropriate, by the competent antitrust and foreign investment control authorities.

It is stated that no final decision has been taken regarding the referred potential transaction nor is there certainty as to whether it will be adopted. Any relevant decision taken on the matter will be disclosed to the market in accordance with applicable regulations.

Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A